Drug Profile
OPA 6566
Alternative Names: OPA-6566Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Otsuka Pharmaceutical
- Developer Kubota Vision; Otsuka Pharmaceutical
- Class Eye disorder therapies
- Mechanism of Action Adenosine A2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Glaucoma; Ocular hypertension
Most Recent Events
- 01 Apr 2020 Acucela is now called Kubota Vision
- 24 Sep 2019 Discontinued - Phase-I/II for Glaucoma in USA (Ophthalmic)
- 24 Sep 2019 Discontinued - Phase-I/II for Ocular hypertension in USA (Ophthalmic)